

Resource Summary Report

Generated by [NIF](#) on Aug 20, 2026

ZR-75-1

RRID:CVCL_0588

Type: Cell Line

Proper Citation

RRID:CVCL_0588

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0588

Proper Citation: RRID:CVCL_0588

Description: Cell line ZR-75-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Invasive breast carcinoma of no special type

Defining Citation: [PMID:688225](#), [PMID:1911442](#), [PMID:3335022](#), [PMID:6582512](#), [PMID:7902062](#), [PMID:10862037](#), [PMID:10969801](#), [PMID:11044355](#), [PMID:11343771](#), [PMID:12353263](#), [PMID:12800145](#), [PMID:15677628](#), [PMID:15767549](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:17334996](#), [PMID:18516279](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:19727395](#), [PMID:20070913](#), [PMID:21378333](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:24389870](#), [PMID:25238572](#), [PMID:25485619](#), [PMID:25699542](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:26759240](#), [PMID:27378269](#), [PMID:28196595](#), [PMID:28287265](#), [PMID:28889351](#), [PMID:29273624](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#)

Comments: Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: JFCR45 cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: ZR-75-1

Synonyms: Zr-75-1, ZR751, ZR75-1, ZR75.1, ZR75_1

Cross References: BTO:BTO_0003136, CLO:CLO_0009727, EFO:EFO_0001262, MCCL:MCC:0000494, CLDB:cl4817, CLDB:cl4818, CLDB:cl4819, CLDB:cl4820, CLDB:cl4821, CLDB:cl4946, AddexBio:C0006011/4901, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:CRL-1500, BCRC:60055, BioGRID_ORCS_Cell_line:339, BioSample:SAMN01821608, BioSample:SAMN03471337, BioSample:SAMN05292440, BioSample:SAMN10988134, cancercellines:CVCL_0588, CancerTools:154547, CCRID:1101HUM-PUMC000090, CCRID:3101HUMTCHu126, Cell_Model_Passport:SIDM00314, ChEMBL-Cells:ChEMBL3307615, ChEMBL-Targets:ChEMBL614393, CLS:300163, Cosmic:687503, Cosmic:755295, Cosmic:871152, Cosmic:877452, Cosmic:894094, Cosmic:904398, Cosmic:934532, Cosmic:944296, Cosmic:979717, Cosmic:991333, Cosmic:997927, Cosmic:1010919, Cosmic:1044205, Cosmic:1046930, Cosmic:1047720, Cosmic:1136344, Cosmic:1152530, Cosmic:1175836, Cosmic:1287904, Cosmic:1289421, Cosmic:1309006, Cosmic:1326279, Cosmic:1523772, Cosmic:1524343, Cosmic:1571792, Cosmic:1603229, Cosmic:1609464, Cosmic:2165028, Cosmic:2301536, Cosmic:2318372, Cosmic:2361354, Cosmic:2668279, Cosmic:2750519, Cosmic:2787556, DepMap:ACH-000097, ECACC:87012601, EGA:EGAS00001000610, GEO:GSM73744, GEO:GSM115120, GEO:GSM155214, GEO:GSM217613, GEO:GSM274660, GEO:GSM344360, GEO:GSM344410, GEO:GSM350508, GEO:GSM378142, GEO:GSM383804, GEO:GSM383805, GEO:GSM383806, GEO:GSM388216, GEO:GSM421897, GEO:GSM481332, GEO:GSM783956, GEO:GSM844725, GEO:GSM845400, GEO:GSM847449, GEO:GSM847509, GEO:GSM887750, GEO:GSM888845, GEO:GSM1008921, GEO:GSM1053721, GEO:GSM1172908, GEO:GSM1173004, GEO:GSM1215256, GEO:GSM1238137, GEO:GSM1374993, GEO:GSM1374994, GEO:GSM1374995, GEO:GSM1401648, GEO:GSM1556182, GEO:GSM1556183, GEO:GSM1556184, GEO:GSM1556185, GEO:GSM1556186, GEO:GSM1664567, GEO:GSM2258740, GEO:GSM2258741, GEO:GSM2258742, GEO:GSM2258743, GEO:GSM2258744, GEO:GSM2258745, GEO:GSM2258746, GEO:GSM2258747, GEO:GSM2258748, GEO:GSM2258749, GEO:GSM2258750, GEO:GSM2258751, GEO:GSM2258752, GEO:GSM2258753, GEO:GSM2258754, GEO:GSM2258755, GEO:GSM2258756, GEO:GSM2258757, GEO:GSM2258956, GEO:GSM2258957, GEO:GSM2258958, IARC_TP53:21111, IBRC:C10099, ICLC:HTL99006, IPD-IMGT/HLA:12334, IZSLER:BS TCL 75, KCB:KCB 2010136YJ, KCLB:21500, LiGeA:CCLE_225, LINCS_HMS:50574, LINCS_LDP:LCL-1321, PharmacDB:ZR751_1689_2019, PRIDE:PXD001327, PRIDE:PXD005390, Progenetix:CVCL_0588, PubChem_Cell_line:CVCL_0588, RCB:RCB1906, SLKBase:3633, TKG:TKG 0189, Wikidata:Q54996114

ID: CVCL_0588

Record Creation Time: 20220427T221743+0000

Record Last Update: 20260816T000246+0000

Ratings and Alerts

No rating or validation information has been found for ZR-75-1.

Warning: Discontinued: RCB; RCB1906

Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870)., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: JFCR45 cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1273 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Peng Y, et al. (2026) SDP-LIV1, a Novel and Optimized LIV-1 Antibody-Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors. *Molecular cancer therapeutics*, 25(2), 322.

Wang J, et al. (2026) Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers. *Cell reports. Medicine*, 7(2), 102577.

Santander GN, et al. (2026) Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. *Cell reports methods*, 101515.

Ohno H, et al. (2026) Label-free imaging of intracellular structures in living mammalian cells via external apodization phase-contrast microscopy. *The FEBS journal*, 293(4), 1127.

Watlington WK, et al. (2026) Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. *Molecular oncology*.

Wang ZW, et al. (2026) Combinatorial inhibition of IGF2BP3-regulated receptor tyrosine kinases offers a new therapeutic strategy for triple-negative breast cancer. *Journal of experimental & clinical cancer research : CR*, 45(1).

Gao Y, et al. (2026) Reprogramming tumour-associated macrophages in breast cancer via si-FOXM1-loaded lipid nanoparticles enhances immune checkpoint inhibitor efficacy. *British journal of pharmacology*, 183(11), 3049.

Herzog SK, et al. (2026) Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer. *Cancer research*, 86(7), 1707.

Zhang D, et al. (2025) Glutamine binds HSC70 to transduce signals inhibiting IFN- γ -mediated immunogenic cell death. *Developmental cell*, 60(14), 1958.

Arnone AA, et al. (2025) Endocrine-targeting therapies shift the breast microbiome to reduce estrogen receptor-?? breast cancer risk. *Cell reports. Medicine*, 6(1), 101880.

Alam R, et al. (2025) Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer. *Cancer discovery*, 15(4), 818.

Bhagwat SV, et al. (2025) Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degradar with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer. *Cancer research*, 85(4), 777.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. *Cell reports. Medicine*, 6(12), 102478.

Peng Z, et al. (2025) YEATS4 reads histone crotonylation to promote fatty acid metabolism and cancer cell stemness. *Cell reports*, 44(10), 116400.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1275.

Komar ZM, et al. (2025) Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal Cells. *Cancers*, 17(13).

Hasan MS, et al. (2025) Sequestration and suppressed synthesis of oncogenic HMGA1 using engineered adenoviruses decreases human pancreatic and breast cancer cell characteristics. *PloS one*, 20(11), e0335934.

Deng N, et al. (2025) Microtubule associated serine/threonine kinase-3 inhibits the malignant phenotype of breast cancer by promoting phosphorylation-mediated ubiquitination degradation of yes-associated protein. *Breast cancer research : BCR*, 27(1), 63.

Abayasiriwardana K, et al. (2025) A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies. *Molecular cancer therapeutics*, 24(7), 976.

Manouchehri JM, et al. (2025) Sulfatase 2 inhibition sensitizes triple-negative breast cancer cells to paclitaxel through augmentation of extracellular ATP. *Cancer biology & therapy*, 26(1), 2483989.